This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Spiriva
  • /
  • Evaluation of Tiotropium 5 µgg/Day Delivered Via t...
Clinical trial

Evaluation of Tiotropium 5 µgg/Day Delivered Via the Respimat� Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

Read time: 2 mins
Last updated:13th Oct 2008
Source: Clinical Trials
Identifier: NCT00772538

The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined as add-on controller therapy on top of usual care in patients with severe persistent asthma.

The primary objective of each trial is to evaluate the long term efficacy of tiotropium over placebo on top of usual care in patients with severe persistent asthma as determined by pulmonary function testing, effects on asthma exacerbations, effects on quality of life, on asthma control and health care resource utilisation. The secondary objective of each trial is to compare the long term safety of tiotropium with placebo in this patient population.

Category Value
Date last updated at source 2014-07-30
Study type(s) Interventional
Study start date 2008-10-13
Estimated primary completion date 2011-07-01

View full details